Bisphosphonates in Osteogenesis Imperfecta

  • Andrew Biggin
  • Craig F. Munns


Osteogenesis imperfecta (OI) is a genetic bone fragility disorder characterised by multiple fractures, reduced bone mass, deformity and disability. Management requires a multidisciplinary approach involving paediatrician, endocrinologist (bone and mineral physician), rehabilitation specialist, orthopaedic surgeon, dentist, physiotherapist and occupational therapist. Bisphosphonate treatment is the mainstay of medical treatment in OI and has been shown to decrease bone pain, enhance well-being and improve mobility and muscle strength, in addition to reducing the incidence of fractures. This chapter summarises the historical use, safety and efficacy of bisphosphonate therapy in children and adolescents with OI.


Osteogenesis Imperfecta Bisphosphonate Therapy Bisphosphonate Treatment Osteogenesis Imperfecta Type Intravenous Pamidronate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors wish to acknowledge the support of the Sydney Medical School Foundation.


  1. 1.
    Russell RGG, Bisaz S, Fleisch H, Currey HL, Rubinstein HM, Dietz AA, et al. Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet. 1970;2(7679):899–902.PubMedCrossRefGoogle Scholar
  2. 2.
    Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12 Suppl):2961–78.PubMedCrossRefGoogle Scholar
  3. 3.
    Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13(4):581–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9(5):745–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42(11):1228–36.PubMedCrossRefGoogle Scholar
  6. 6.
    Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008;(4):CD005088.Google Scholar
  7. 7.
    Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101–16.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, et al. A single recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet. 2012;91(2):343–8.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2011;88(3):362–71.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone. 2007;40(3):638–44.PubMedCrossRefGoogle Scholar
  11. 11.
    Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone. 2002;31(1):12–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell. 2006;127(2):291–304.PubMedCrossRefGoogle Scholar
  13. 13.
    Byers PH. Etiology of osteogenesis imperfecta: an overview of biochemical and molecular genetic analyses. Connect Tissue Res. 1995;31(4):257–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Ben Amor IM, Glorieux FH, Rauch F. Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta. J Osteoporos. 2011;2011:540178.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, Aktas D, et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2010;86(4):551–9.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M, Alrasheed S, et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet. 2010;86(3):389–98.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Lapunzina P, Aglan M, Temtamy S, Caparros-Martin JA, Valencia M, Leton R, et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet. 2010;87(1):110–4.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Misof K, Landis WJ, Klaushofer K, Fratzl P. Collagen from the osteogenesis imperfecta mouse model (oim) shows reduced resistance against tensile stress. J Clin Invest. 1997;100(1):40–5.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000;26(6):581–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Sillence DO, Morley K, Ault JE. Clinical management of osteogenesis imperfecta. Connect Tissue Res. 1995;31(4):S15–21.PubMedCrossRefGoogle Scholar
  21. 21.
    Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987;16(5):360–3.PubMedCrossRefGoogle Scholar
  22. 22.
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339(14):947–52.PubMedCrossRefGoogle Scholar
  23. 23.
    Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr. 1998;87(1):64–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85(5):1846–50.PubMedGoogle Scholar
  25. 25.
    Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, et al. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr. 2013;79(6):333–40.PubMedCrossRefGoogle Scholar
  26. 26.
    Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest. 2002;110(9):1293–9.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N, et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int. 2003;72(2):103–12.PubMedCrossRefGoogle Scholar
  28. 28.
    Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2012;25(5–6):485–91.PubMedGoogle Scholar
  29. 29.
    Ruck J, Dahan-Oliel N, Montpetit K, Rauch F, Fassier F. Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year. J Child Orthop. 2011;5(3):217–24.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004;363(9419):1427–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Rauch F, Munns CF, Land C, Cheung M, Glorieux FH. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res. 2009;24(7):1282–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Ward LM, Rauch F, Whyte MP, D’Astous J, Gates PE, Grogan D, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. Journal of Clinical Endocrinology & Metabolism. 2011;96(2):355–64.CrossRefGoogle Scholar
  33. 33.
    Bishop N, Adami S, Ahmed SF, AntÛn J, Arundel P, Burren CP, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. The Lancet. 2013;382:1424–32.CrossRefGoogle Scholar
  34. 34.
    Rauch F, Cornibert S, Cheung M, Glorieux FH. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone. 2007;40(4):821–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Biggin A, Zheng L, Briody J, McQuade M, Munns CF. Long-term effects of bisphosphonate therapy in children with osteogenesis imperfecta. Bone Abstracts. 2013;2:OP13.Google Scholar
  36. 36.
    Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17(6):897–907.PubMedCrossRefGoogle Scholar
  37. 37.
    Bachrach LK, Ward LM. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab. 2009;94(2):400–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, et al. Circulating gammadelta T cells and the risk of acute-phase response after zoledronic acid administration. J Bone Miner Res. 2012;27(1):227–30.PubMedCrossRefGoogle Scholar
  39. 39.
    Robinson RE, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD. Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy. 2004;24(2):195–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab. 2003;88(3):986–92.PubMedCrossRefGoogle Scholar
  41. 41.
    Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone. 2004;35(1):231–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics. 2003;111(5 Pt 1):1030–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003;349(5):457–63.PubMedCrossRefGoogle Scholar
  44. 44.
    Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res. 2004;19(7):1191–3.PubMedCrossRefGoogle Scholar
  45. 45.
    Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19(11):1779–86.PubMedCrossRefGoogle Scholar
  46. 46.
    Malmgren B, Astrom E, Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med. 2008;37(4):196–200.PubMedCrossRefGoogle Scholar
  47. 47.
    Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 2011;49(1):103–10.PubMedCrossRefGoogle Scholar
  48. 48.
    Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res. 2004;19(10):1742–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002;86(5):356–64.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Institute of Endocrinology and DiabetesUniversity of Sydney, The Children’s Hospital at WestmeadWestmeadAustralia

Personalised recommendations